Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilenya Could Surpass Avonex Market Share, Analysts Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis' Gilenya is fresh out of the gate, but stands to collect a large share of the MS market, Leerink Swann analysts predict in a report.

You may also be interested in...



Emerging MS Treatments: Reading the Gilenya Tea Leaves

The closely watched launch of Gilenya, the first oral treatment for multiple sclerosis, may have changed the game for developing new therapies for the disease. Start-Up profiles four emerging MS drug developers: Allozyne, GeNeuro, Nuron Biotech and Receptos.

Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?

Since his arrival as CEO nearly seven months ago, Biogen Idec Inc.’s George Scangos has been exerting his influence in ways both big and small. None may have more lasting impact than his recruitment of two top industry executives, Steven Holtzman and Doug Williams, to take the reins respectively as Biogen’s executive VP of corporate development and executive VP of R&D.

Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?

Since his arrival as CEO nearly seven months ago, Biogen Idec Inc.’s George Scangos has been exerting his influence in ways both big and small. None may have more lasting impact than his recruitment of two top industry executives, Steven Holtzman and Doug Williams, to take the reins respectively as Biogen’s executive VP of corporate development and executive VP of R&D.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel